Continued CSL312 treatment for children with hereditary angioedema
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the full treatment period in the earlier CSL312 study (NCT05819775).
- CSL312 worked well for you, with no or very few swelling attacks during that study.
- You did not have any serious side effects from CSL312.
- Your doctor agrees that continuing CSL312 is still helpful for you.
- There is no other approved preventive treatment that would work better for you.
- You are under 12 years old (or the study team can discuss exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.